Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PEDIADEX randomized controlled trial
2025-521039-35-00Phase 3Authorised
- Sponsor
- CHRU Tours
- Start
- Oct 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of dexmedetomidine in delirium, agitation, pain and 1 more (2 arms), sponsored by CHRU Tours. Primary endpoint: Proportion of children with at least one episode of delirium. Planned start Oct 2025; status: authorised.
02
Drugs
dexmedetomidine
03
Conditions
deliriumagitationpainanxiety disorder
Beyond the preview
Go deeper on 2025-521039-35-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-521039-35-00.